OBI Pharma Collaborates with GlyTech for Enhanced Glycan Production
In an exciting development, OBI Pharma, Inc., a clinical-stage global oncology company, has announced a strategic collaboration with GlyTech, Inc., a leading Japanese manufacturer renowned for its expertise in glycan production and glycosylation technologies. This alliance aims to expand the reach of OBI's GlycOBI® enabling technologies in the pharmaceutical sector across Japan.
Understanding the Collaboration Agreements
The partnership is formalized through a Marketing Agreement and a Material Transfer Agreement. Under the Marketing Agreement, OBI allows GlyTech the rights to promote and market GlycOBI® ADC enabling technologies, powered by EndoSymeOBI®, to pharmaceutical and biotech firms within Japan. GlyTech's role extends to being a vital supplier of glycans across the region.
Furthermore, the Material Transfer Agreement enables OBI to share its advanced materials with GlyTech, which will facilitate research aimed at enhancing the efficient production of glycans for antibody-drug conjugates (ADCs).
Perspectives from Company Leaders
Heidi Wang, Ph.D., the CEO of OBI Pharma, expressed her enthusiasm about the collaboration. She stated, “GlyTech has been a trusted partner for high-quality glycans, and we are eager to work together to extend the impact of our innovative GlycOBI® ADC enabling technologies with potential partners in Japan. Our collaborative research also aligns with our mission to secure high-quality, scalable glycan manufacturing for ADCs.”
Hiroaki Asai, the President and CEO of GlyTech, commented on the significance of the collaboration, noting, “OBI Pharma's groundbreaking GlycOBI® ADC technologies showcase their mastery in enzyme-based synthetic organic chemistry. GlyTech is proud to contribute by providing highly pure human glycans, integral to these advanced technologies. We look forward to OBI Pharma's continued advancements in drug development.”
About OBI Pharma, Inc.
Founded in 2002 and headquartered in Taiwan, OBI Pharma, Inc. specializes in the development of innovative cancer therapies, including antibody-drug conjugates (ADCs) and active immunotherapies. Their pipeline includes promising candidates such as OBI-992, OBI-902, and OBI-904, which target specific cancer biomarkers TROP2 and Nectin-4.
In addition to ADC technologies, OBI Pharma is advancing its immuno-oncology portfolio with active immunotherapy vaccines targeting Globo H. They are also developing a novel small-molecule prodrug, OBI-3424, which offers a targeted approach for delivering potent antitumor agents directly to tumors exhibiting high levels of the AKR1C3 enzyme.
About GlyTech, Inc.
Established in 2012, GlyTech, Inc. is based in Kyoto, Japan and stands out as the sole bio-venture company globally focused on the commercial production of human-type glycans. Their mission is to promote health and wellness by creating advanced products that harness the potential of glycans and other biochemicals.
The company is at the forefront of integrating glycan technologies into pharmaceuticals. Their technological offerings also include enhancing drug delivery to the brain and discovering peptide binders, with ongoing clinical trials for a glycosylated somatostatin targeting acromegaly.
Frequently Asked Questions
What is the focus of the collaboration between OBI Pharma and GlyTech?
The collaboration aims to expand OBI's GlycOBI® enabling technologies in Japan and enhance glycan production for ADCs.
What agreements have been made between the two companies?
They entered into a Marketing Agreement for promoting technologies and a Material Transfer Agreement for sharing advanced materials for research.
Who is OBI Pharma, Inc.?
OBI Pharma, Inc. is a clinical-stage company based in Taiwan, focusing on developing novel cancer therapies.
What does GlyTech specialize in?
GlyTech specializes in the commercial production of human-type glycans and enhancing drug delivery technologies.
What are ADCs?
Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine an antibody with a cytotoxic drug to selectively kill cancer cells.
